{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:19:28Z","timestamp":1791231568870,"version":"4.1.0"},"reference-count":32,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,2,2]],"date-time":"2023-02-02T00:00:00Z","timestamp":1675296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Charles University research program Cooperatio Internal Disciplines"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Atopic dermatitis is a chronic inflammatory intensively pruritic skin disease. Patients with moderate-to-severe atopic dermatitis or with difficult-to-treat areas are candidates for systemic therapy, especially when topical therapy is inadequate. Currently, we have available not only conventional immunosuppressive systemic therapy, but also targeted biological therapy, which has shown a remarkable reduction in clinical severity with a good safety profile. Dupilumab has been approved to treat moderate-to-severe atopic dermatitis. Even though the therapy has been available for more than 3 years, there are still limited data regarding the treatment of patients with concomitant cancer. Previous immunosuppressive treatment for atopic dermatitis, such as cyclosporine or azathioprine, poses a safety risk for patients with malignant disease. We present a case series of three patients with advanced cancer and severe atopic dermatitis treated with dupilumab for an average of 17 months with a great response toward atopic dermatitis without cancer recurrence. One patient had colorectal cancer\u2019 the second and the third both had cancer duplicity\u2014colorectal and kidney cancer and penile squamous cell carcinoma with prostate cancer. Our cases suggest that dupilumab can safely control atopic dermatitis in patients with advanced cancer.<\/jats:p>","DOI":"10.3390\/jcm12031191","type":"journal-article","created":{"date-parts":[[2023,2,3]],"date-time":"2023-02-03T01:40:25Z","timestamp":1675388425000},"page":"1191","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Treatment of Severe Atopic Dermatitis with Dupilumab in Patients with Advanced Cancer"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1885-2132","authenticated-orcid":false,"given":"Milena","family":"Tanczosova","sequence":"first","affiliation":[{"name":"Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, 10034 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4341-3812","authenticated-orcid":false,"given":"Jan","family":"Hugo","sequence":"additional","affiliation":[{"name":"Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, 10034 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spyridon","family":"Gkalpakiotis","sequence":"additional","affiliation":[{"name":"Department of Dermatovenereology, Third Faculty of Medicine, Charles University and Kralovske Vinohrady University Hospital, 10034 Prague, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,2,2]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/all.13401","article-title":"Epidemiology of atopic dermatitis in adults: Results from an international survey","volume":"73","author":"Barbarot","year":"2018","journal-title":"Allergy"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Bieber, T. (2010). Atopic dermatitis. Ann. Dermatol., 22.","DOI":"10.5021\/ad.2010.22.2.125"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4168\/aair.2011.3.2.67","article-title":"The atopic march: Progression from atopic dermatitis to allergic rhinitis and asthma","volume":"3","author":"Zheng","year":"2011","journal-title":"Allergy Asthma Immunol. Res."},{"key":"ref_4","first-page":"359","article-title":"Inside out or outside in: Does atopic dermatitis disrupt barrier function or does disruption of barrier function trigger atopic dermatitis?","volume":"96","author":"Silverberg","year":"2015","journal-title":"Cutis"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1080\/09546634.2020.1713971","article-title":"The atopic dermatitis itch scale: Development of a new measure to assess pruritus in patients with atopic dermatitis","volume":"31","author":"Martin","year":"2020","journal-title":"J. Dermatolog. Treat."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s40257-018-0383-4","article-title":"Major comorbidities of atopic dermatitis: Beyond allergic disorders","volume":"19","author":"Paller","year":"2018","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1097\/DER.0000000000000401","article-title":"Sleep disturbance and sleep-related impairment in adults with atopic dermatitis: A cross-sectional study","volume":"29","author":"Li","year":"2018","journal-title":"Dermatitis"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1080\/03007995.2016.1195733","article-title":"The burden of atopic dermatitis in US adults: Results from the 2013 National Health and Wellness Survey","volume":"32","author":"Whiteley","year":"2016","journal-title":"Curr. Med. Res. Opin."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Wan, J., Shin, D.B., and Syed, M.N. (2022). 31772 malignancy risk among children and adults with atopic dermatitis in a population-based cohort. J. Am. Acad. Dermatol., 87.","DOI":"10.1016\/j.jaad.2022.06.350"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.jaad.2006.05.048","article-title":"The burden of skin diseases: 2004: A joint project of the American Academy of Dermatology Association and the Society for Investigative Dermatology","volume":"55","author":"Bickers","year":"2006","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"606","DOI":"10.20344\/amp.11963","article-title":"Update on atopic dermatitis","volume":"32","author":"Torres","year":"2019","journal-title":"Acta Med. Port."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1111\/jdv.14888","article-title":"Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: Part, I.I","volume":"32","author":"Wollenberg","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/j.jaci.2021.08.009","article-title":"JAK inhibitors in the treatment of atopic dermatitis","volume":"148","author":"Chovatiya","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/all.12339","article-title":"Systemic therapy for atopic dermatitis","volume":"69","author":"Simon","year":"2014","journal-title":"Allergy"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): A 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jaad.2020.08.051","article-title":"Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis","volume":"84","author":"Halling","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1080\/17512433.2018.1449642","article-title":"Dupilumab for treatment of atopic dermatitis","volume":"11","author":"Srour","year":"2018","journal-title":"Expert Rev. Clin. Pharmacol."},{"key":"ref_19","unstructured":"(2023, January 13). FDA\/CEDR Resources Page. Food and Drug Administration Web Site, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/761055s044lbl.pdf."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40264-017-0636-9","article-title":"Potential risks related to modulating interleukin-13 and interleukin-4 signalling: A systematic review","volume":"41","author":"Braddock","year":"2018","journal-title":"Drug Saf."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"899","DOI":"10.2340\/00015555-3201","article-title":"Two Cancer Patients Receiving Dupilumab for Treatment of Atopic Dermatitis","volume":"99","author":"Fowler","year":"2019","journal-title":"Acta Derm. Venereol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Qiu, Y., Ali, K., Lou, H., Shan, J., and Wu, L. (2022). Successful Treatment of Atopic Dermatitis with Dupilumab in a Patient with Non-Hodgkin\u2019s Lymphoma. Acta Derm.-Venereol., 102.","DOI":"10.2340\/actadv.v101.224"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1080\/09546634.2022.2043545","article-title":"Dupilumab for the treatment of atopic dermatitis: Realworld data from the Czech Republic BIOREP registry","volume":"33","author":"Cetkovska","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"124","DOI":"10.18176\/jiaci.0641","article-title":"Use of dupilumab in 543 adult patients with moderate-to-severe atopic dermatitis: A multicenter, retrospective study","volume":"32","author":"Nettis","year":"2022","journal-title":"J. Investig. Allergol. Clin. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Siliquini, N., Viola, R., Giura, M.T., Fierro, M.T., Ribero, S., and Ortoncelli, M. (2020). Case of bladder cancer during Dupilumab therapy: Just an incidental event?. Dermatol. Ther., 33.","DOI":"10.1111\/dth.13854"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.clml.2022.09.002","article-title":"Dupilumab in Multiple Myeloma: A Case Series","volume":"22","author":"Owji","year":"2022","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_27","unstructured":"(2023, January 13). Neoadjuvant Dupilumab in Men with Localized High-Risk Prostate Cancer\u2014Full Text View (No Date) Full Text View\u2014ClinicalTrials.gov, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03886493."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Fitzgerald, B.G., Marron, T.U., Hall, N., O\u2019Grady, D., LaMarche, N., Hennequin, C., Hegde, S., Maier, B., Le Berichel, J., and Chadda, U. (2022). A phase 1b\/2 trial of dupilumab given in conjunction with pd-(l)1 blockade in the treatment of relapsed\/refractory metastatic NSCLC. J. Clin. Oncol., 40.","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS9139"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Wollenberg, A., Thomsen, S.F., Lacour, J.P., Jaumont, X., and Lazarewicz, S. (2021). Targeting immunoglobulin E in atopic dermatitis: A review of the existing evidence. World Allergy Organ. J., 14.","DOI":"10.1016\/j.waojou.2021.100519"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1784","DOI":"10.1093\/annonc\/mdv231","article-title":"IGE and risk of cancer in 37 747 individuals from the general population","volume":"26","author":"Helby","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/CE.S133661","article-title":"Dupilumab: An evidence-based review of its potential in the treatment of atopic dermatitis","volume":"13","author":"Eshtiaghi","year":"2018","journal-title":"Core Evid."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1080\/09546634.2020.1773379","article-title":"A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis","volume":"33","author":"Fargnoli","year":"2022","journal-title":"J. Dermatol. Treat."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/3\/1191\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:22:26Z","timestamp":1760120546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/3\/1191"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,2]]},"references-count":32,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,2]]}},"alternative-id":["jcm12031191"],"URL":"https:\/\/doi.org\/10.3390\/jcm12031191","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,2]]}}}